Helus Pharma Inc. (HELP) Stock Price, Quote & News

Company Profile

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterate...

Industry: Biotechnology

Sector: Healthcare

Phone: 908-764-8385

Website: www.helus.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

RuddyRolls Jul. 20 at 2:39 AM

@laidbacklu $DFTX $CMPS COMP360 (TRD) will be deployed off-label no doubt - as only approved in first few years. $HELP has a candidate for Generalized Anxiety Disorder (GAD): HLP004. "A proprietary deuterated formulation of $N,N$-dimethyltryptamine (DMT) administered via intramuscular injection, paired with psychotherapy. Clinical Findings: Topline Phase 2 data revealed clinically meaningful reductions in anxiety, with durable remission rates extending up to six months following treatment, and no drug-related serious adverse events reported. Patent Protection: Helus Pharma holds robust intellectual property and patent coverage for this deuterated DMT program." https://finance.yahoo.com/news/cybin-help-down-27-3-131141505.html

1 · Reply

CuriousChimps Jul. 20 at 1:16 AM

$HELP this is the next in line for a multi billion market cap.

0 · Reply

RuddyRolls Jul. 19 at 11:07 PM

$CMPS $DFTX $HELP Strong point. But doesn't explain why CMPS is 4x HELP mkt cap (2x might be about right - efficacy aside, relative just to time to outcome) and DFTX is 3.5 almost 4x CMPS mkt cap. Perhaps then it appears that DFTX is appropriately priced given probable TAM in a multi-player market - and both CMPS and HELP are due to triple. Or perhaps DFTX is due to double again and the others 6x. Lets see.

4 · Reply

Millionaire11 Jul. 19 at 8:15 PM

$CMPS $DFTX $HELP

0 · Reply

Millionaire11 Jul. 19 at 1:37 AM

$CMPS $HELP

1 · Reply

snaches Jul. 19 at 12:25 AM

$GOD.X $HELP $BTC.X 😉

0 · Reply

Cybin Jul. 18 at 11:49 PM

$HELP #3 trending 😎📈 prioritize mental health treatment ❗️🍄

0 · Reply

Horseman23 Jul. 18 at 11:30 PM

$HELP I smell a buyout

0 · Reply

RuddyRolls Jul. 18 at 11:11 PM

$HELP we trending on the weekend.

0 · Reply

RuddyRolls Jul. 18 at 11:00 PM

$HELP New entrants to Big Pharma land are few and far between. Massive moat, requires a blockbuster. Gemini commentary on the impact of Prozac on Lilly. "Redefining Modern Psychiatry Prozac (fluoxetine) The Company: Launched by Eli Lilly. The Impact: As the first blockbuster SSRI antidepressant, it became a cultural phenomenon in the late 1980s. The massive cash flows elevated Lilly from a standard Midwestern U.S. drugmaker into a permanent fixture of global Big Pharma"

0 · Reply

Helus Pharma price target lowered to $45 from $48 at Guggenheim

ATAI GHRS LLY

2026-07-14T13:41:08.000Z - 5 days ago

Helus Pharma price target lowered to $15 from $30 at Alliance Global

2026-07-09T13:50:15.000Z - 10 days ago

Psychedelic: Compass Pathways reports six-month data for psilocybin drug

ATAI CMND CMPS DFTX

2026-07-09T10:05:14.000Z - 10 days ago

Helus Pharma price target lowered to $70 from $95 at H.C. Wainwright

2026-07-01T10:40:45.000Z - 18 days ago

Helus Pharma price target lowered to $42 from $45 at Canaccord

Jun 29, 2026, 7:40 AM EDT - 20 days ago

Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

Jun 29, 2026, 7:00 AM EDT - 20 days ago

Cybin Annual report: Q4 2026

Jun 29, 2026, 7:00 AM EDT - 20 days ago

Cybin Earnings release: Q4 2026

Jun 29, 2026, 7:00 AM EDT - 20 days ago

Cybin Slides: Corporate presentation

Jun 25, 2026, 9:27 AM EDT - 24 days ago

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

2026-06-24T10:35:20.000Z - 25 days ago

Helus Pharma prices 10.31M common shares at $4.85 in public offering

2026-06-24T10:05:22.000Z - 25 days ago

Helus Pharma says enrollment in APPROACH Phase 3 trial ‘progressing as planned’

Jun 24, 2026, 6:01 AM EDT - 25 days ago

Helus Pharma™ Announces US$50 Million Underwritten Offering

Jun 24, 2026, 6:00 AM EDT - 25 days ago

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

Jun 15, 2026, 7:00 AM EDT - 4 weeks ago

Cybin Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 11, 2026, 7:30 AM EDT - 5 weeks ago

Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference

Jun 4, 2026, 2:35 PM EDT - 6 weeks ago

Cybin Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 7:30 AM EDT - 6 weeks ago

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

Apr 30, 2026, 7:17 PM EDT - 2 months ago

CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 30, 2026, 7:30 AM EDT - 2 months ago

Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference

Apr 28, 2026, 7:30 AM EDT - 2 months ago

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 23, 2026, 7:30 AM EDT - 3 months ago

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

Apr 20, 2026, 2:05 PM EDT - 3 months ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS DFTX GHRS

2026-04-20T14:47:00.000Z - 3 months ago

Helus ‘welcomes’ Executive Order for accelerating psychedelic research

2026-04-20T12:41:24.000Z - 3 months ago

Helus Pharma announces Cola is stepping down as CEO, appoints So as Interim CEO

Apr 20, 2026, 8:15 AM EDT - 3 months ago

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

Apr 20, 2026, 6:43 AM EDT - 3 months ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX ENVB GHRS

Apr 16, 2026, 7:30 AM EDT - 3 months ago

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Cybin Slides: Corporate presentation

Mar 12, 2026, 7:30 AM EDT - 4 months ago

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Mar 5, 2026, 7:30 AM EST - 4 months ago

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Mar 5, 2026, 7:30 AM EST - 4 months ago

Cybin Transcript: Study result

Mar 5, 2026, 7:30 AM EST - 4 months ago

Cybin Press release: Study result

Mar 5, 2026, 7:30 AM EST - 4 months ago

Cybin Slides: Study result

Feb 24, 2026, 7:45 AM EST - 5 months ago

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Feb 17, 2026, 7:30 AM EST - 5 months ago

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Feb 13, 2026, 12:30 PM EST - 5 months ago

Cybin Earnings release: Q3 2026

Feb 13, 2026, 7:31 AM EST - 5 months ago

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Dec 30, 2025, 3:33 PM EST - 7 months ago

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 19, 2025, 7:00 AM EST - 7 months ago

Cybin Registration statement: Registration Filing

Dec 18, 2025, 12:29 PM EST - 7 months ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Nov 17, 2025, 7:30 AM EST - 8 months ago

Cybin Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Cybin Earnings Call Transcript: Q2 2026

Nov 13, 2025, 8:00 AM EST - 8 months ago

Cybin Earnings release: Q2 2026

Nov 13, 2025, 7:20 AM EST - 8 months ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:30 AM EST - 8 months ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 10, 2025, 4:30 PM EST - 8 months ago

Cybin Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:30 AM EST - 9 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 2:00 PM EST - 9 months ago

Cybin Transcript: Future of Health Summit 2025

Nov 5, 2025, 7:30 AM EST - 9 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 9 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 9 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 9 months ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 9 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 10 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 17, 2025, 9:20 AM EDT - 10 months ago

Cybin Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 17, 2025, 8:00 AM EDT - 10 months ago

Cybin Registration statement: Registration Filing

Sep 11, 2025, 7:30 AM EDT - 11 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 11:00 AM EDT - 11 months ago

Cybin Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:30 AM EDT - 11 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 5, 2025, 10:20 AM EDT - 11 months ago

Cybin Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 7:30 AM EDT - 11 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 11 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 11 months ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 11 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 11 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 10:00 AM EDT - 11 months ago

Cybin Transcript: AGM 2025

Aug 13, 2025, 5:30 PM EDT - 1 year ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Cybin Earnings release: Q1 2026

Aug 12, 2025, 2:30 PM EDT - 1 year ago

Cybin Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Cybin Registration statement: Registration Filing

Jul 17, 2025, 7:30 AM EDT - 1 year ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 1 year ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 12:00 AM EDT - 1 year ago

Cybin Earnings release: Q4 2025

Jul 1, 2025, 12:00 AM EDT - 1 year ago

Cybin Annual report: Q4 2025

Jun 30, 2025, 10:03 PM EDT - 1 year ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 9:27 PM EDT - 1 year ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 13, 2025, 7:45 AM EDT - 1 year ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

RuddyRolls Jul. 20 at 2:39 AM

1 · Reply

CuriousChimps Jul. 20 at 1:16 AM

$HELP this is the next in line for a multi billion market cap.

0 · Reply

RuddyRolls Jul. 19 at 11:07 PM

4 · Reply

Millionaire11 Jul. 19 at 8:15 PM

$CMPS $DFTX $HELP

0 · Reply

Millionaire11 Jul. 19 at 1:37 AM

$CMPS $HELP

1 · Reply

snaches Jul. 19 at 12:25 AM

$GOD.X $HELP $BTC.X 😉

0 · Reply

Cybin Jul. 18 at 11:49 PM

$HELP #3 trending 😎📈 prioritize mental health treatment ❗️🍄

0 · Reply

Horseman23 Jul. 18 at 11:30 PM

$HELP I smell a buyout

0 · Reply

RuddyRolls Jul. 18 at 11:11 PM

$HELP we trending on the weekend.

0 · Reply

RuddyRolls Jul. 18 at 11:00 PM

0 · Reply

RuddyRolls Jul. 18 at 10:58 PM

$HELP "Read that timeline again, because it is the whole story. Lilly committed up to $3.8 billion for an asset whose pivotal data is nearly three years out. That was not a purchase of proven revenue. It was a purchase of position, by a company that had already pledged more than $10 billion in upfront payments across eight acquisitions this year while building a neuroscience franchise alongside its obesity and diabetes business. Lilly has history here: Prozac reshaped the treatment of depression and powered its last great expansion before the GLP-1 era."

0 · Reply

RuddyRolls Jul. 18 at 10:49 PM

$HELP Nails it. "The Deal That Changed the Conversation What Lilly bought is instructive. AtaiBeckley's lead asset, BPL-003, is an intranasal formulation of 5-MeO-DMT for treatment-resistant depression, and it holds FDA Breakthrough Therapy Designation. Phase 2b results linked it to statistically significant improvement beginning on Day 2, maintained through Day 57. The company is also advancing an MDMA-related program. Phase 3 topline data for BPL-003 is not expected until early 2029."

0 · Reply

RuddyRolls Jul. 18 at 10:46 PM

$HELP Instructive PR drop from HQ. https://www.tradingview.com/news/prnewswire:40eea419ea8f2:0-big-pharma-just-paid-up-to-3-8-billion-for-psychedelic-medicine-and-the-rest-of-the-sector-is-being-repriced-in-real-time/

0 · Reply

JuliusW Jul. 18 at 6:40 PM

$HELP and this is the one I still hold. With a phase 3, this is 100% going to be bought. Big Pharma always facing expiration of patents, looking at the concrete possibility of this sector's moving into mainstream treatment protocols.

1 · Reply

Horseman23 Jul. 18 at 1:05 PM

$HELP getting bought out next - get ready

1 · Reply

leLu83 Jul. 18 at 1:17 AM

$HELP with the massive dilution and weak efficacy, this will be $1.50 in 6 months

1 · Reply

jlcTrader86 Jul. 17 at 9:20 PM

$HELP

2 · Reply

RuddyRolls Jul. 17 at 8:48 PM

$HELP One other contender with$100B potential. Will be fascinating to see how they design consumer-facing brands.

0 · Reply

ChristopherMcC Jul. 17 at 8:33 PM

$HELP a step in the right direction? Maybe. Just remember the history of one step forward, five steps backwards..

1 · Reply

RuddyRolls Jul. 17 at 8:15 PM

$HELP yes OPEX (today) is only once a month for this ticker. Which is excellent as its therefore largely unhampered by the mechanics of derivatives and can therefore move a lot more freely than those that have the typical weekly (Friday) expiry in the background. Saying that Monday should be a good day now that the$7.50 strike wall has passed. The options chain is odd here - only 5 strikes in increments of $2.50. Not much action in it clearly - so far! ;)

0 · Reply

BobJohnBuoy666 Jul. 17 at 7:26 PM

$HELP actually looks good for once, suspiciously good. Either buyout or rug pull, we will find out

0 · Reply

HelusPharmaIR Jul. 17 at 5:40 PM

$HELP Great to see the interest in the space and in HELP. We don't comment on market movements, but we're glad to point to what matters for the program, and there are three things worth watching for our pipeline. First, the FDA's recent guidance on how psychedelic therapies should be studied, which sets a clearer framework for the whole field. Second, HLP003's Phase 2 profile in major depressive disorder: roughly a 23-point MADRS improvement and 71% remission at 12 months after a two-dose course. Third, and most important, the Phase 3 APPROACH readout, with topline data expected in Q4 2026.

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	864,772
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A